


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

OTPE MP40
FEB 15 2006
PATENT & TRADEMARK OFFICE

[illegible]

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ^o
		Country Code ² Number ³ Kind Code ³ (if known)				
	FP1					
	FP2					
	FP3					
	FP4					
	FP5					
	FP6					
	FP7					
	FP8					
	FP9					

Examiner Signature		Date Considered	11/13/07
-----------------------	---	--------------------	----------

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete if Known			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/824,357		
		Filing Date	April 15, 2004		
		First Named Inventor	Najib BABUL		
		Art Unit	1617		
		Examiner Name	Kim, Jennifer M.		
Sheet	1	of	1	Attorney Docket Number	2039.0010001

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published	T ²
<i>✓</i>	AS9	International Search Report for International Application No. PCT/US04/11979, ISA/US, Alexandria, Virginia, mailed November 9, 2005.	
<i>✓</i>	AT9	International Preliminary Report for International Application No. PCT/US2004/011979, the International Bureau of WIPO, Geneva, Switzerland, issued November 25, 2005.	


495030_1.DOC

Examiner Signature		Date Considered	11/13/07
--------------------	---	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 2039.0010001	APPLICATION NO. 10/824,357
	APPLICANT Najib BABUL	
	FILING DATE April 15, 2004	GROUP 1617

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
2	AA1	4,486,436	12/04/1984	Sunshine et al.	2		03/11/1983
	AB1	4,567,183	01/28/1986	Sunshine et al.			12/12/1983
	AC1	4,777,174	10/11/1988	Sunshine et al.			03/02/1987
	AD1	4,965,065	10/23/1990	Lukacsko et al.			02/06/1987
	AE1	5,043,358	08/27/1991	Lukacsko et al.			09/04/1990
	AF1	5,071,842	12/10/1991	Lukacsko et al.			12/21/1989
	AG1	5,321,012	06/14/1994	Mayer et al.			04/06/1993
	AH1	5,767,125	06/16/1998	Crain et al.			12/03/1996
	AI1	6,007,841	12/28/1999	Caruso, F.S.			03/13/1998
	AJ1	6,054,451	04/25/2000	Caruso, F.S.			04/21/1998
	AK1	6,117,871	09/12/2000	Maurer et al.			11/25/1996

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)			
2	AR	1	Aronoff, G.M., and Gallagher, R.M., "Chapter 32. Pharmacological Management of Chronic Pain: A Review," in <i>Evaluation and Treatment of Chronic Pain</i> , 3 rd edition, Mitchell, C.W., ed., pp. 433-453, Williams & Wilkins, Baltimore, MD (1999).
	AS	1	Beaver, W.T., "Chapter 33. Nonsteroidal Anti-Inflammatory Analgesics and Their Combinations with Opioids," in <i>Evaluation and Treatment of Chronic Pain</i> , 3 rd edition, Mitchell, C.W., ed., pp. 455-473, Williams & Wilkins, Baltimore, MD (1999).
	AT	1	Cherny, N.I., and Portenoy, R.K., "Chapter 66. Practical issues in the management of cancer pain," in <i>Textbook of Pain</i> , 4 th edition, Wall, P.D., and Melzack, R., eds., pp. 1479-1522, Harcourt Publishers Limited, London, England (1999).
EXAMINER			DATE CONSIDERED 11/13/07
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.			

FORM PTO-1449 <u>INFORMATION DISCLOSURE STATEMENT</u>	ATTY. DOCKET NO. 2039.0010001	APPLICATION NO. 10/824,357
	APPLICANT Najib BABUL	
	FILING DATE April 15, 2004	GROUP 1617

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
<i>K</i>	AA2	6,160,020	12/12/2000	Ohannesian et al.	<i>2</i>		06/19/1998
<i>K</i>	AB2	6,187,338 B1	02/13/2001	Caruso et al.	<i>2</i>		02/22/1999
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)			
<i>K</i>	AR	<u>2</u>	Grass, S., et al., "N-methyl-D-aspartate receptor antagonists potentiate morphine's antinociceptive effect in the rat," <i>Acta Physiol. Scand.</i> 158:269-273, Scandinavian Physiological Society (1996).
<i>K</i>	AS	<u>2</u>	Jackson, L.M., and Hawkey, C.J., "COX-2 Selective Nonsteroidal Anti-Inflammatory Drugs: Do They Really Offer Any Advantages?" <i>Drugs</i> 59:1207-1216, Adis International Limited (2000).
<i>K</i>	AT	<u>2</u>	Kamali, F., "Rofecoxib Merck & Co Inc," <i>Current Opinion in CPNS Investigational Drugs</i> 1:126-131, Current Drugs Ltd (1999).
EXAMINER <i>[Signature]</i>			DATE CONSIDERED <i>11/13/04</i>
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.			

FORM PTO-1449 <u>INFORMATION DISCLOSURE STATEMENT</u>	ATTY. DOCKET NO. 2039.0010001	APPLICATION NO. 10/824,357
	APPLICANT Najib BABUL	
	FILING DATE April 15, 2004	GROUP 1617

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						



FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)			
	AR	<u>3</u>	Katz, N.P., "MorphiDex" (MS:DM) Double-Blind, Multiple-Dose Studies in Chronic Pain Patients," <i>J. Pain Symptom Manage.</i> 19 (Suppl.):S37-S41, Elsevier (2000).
	AS	<u>3</u>	Kauppila, T., et al., "Dextromethorphan potentiates the effect of morphine in rats with peripheral neuropathy," <i>Neuroreport</i> 9:1071-1074, Rapid Science Ltd (1998).
	AT	<u>3</u>	Laudanno, O.M., et al., "Gastrointestinal Damage Induced by Celecoxib and Rofecoxib in Rats," <i>Dig. Dis. Sci.</i> 46:779-784, Plenum Publishing Corporation (2001).
EXAMINER DATE CONSIDERED 11/13/07			
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.			

FORM PTO-1449 <u>INFORMATION DISCLOSURE STATEMENT</u>	ATTY. DOCKET NO. 2039.0010001	APPLICATION NO. 10/824,357
	APPLICANT Najib BABUL	
	FILING DATE April 15, 2004	GROUP 1617

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						



FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)				
	AR	<u>4</u>	Mao, J., et al., "Oral administration of dextromethorphan prevents the development of morphine tolerance and dependence in rats," Pain 67:361-368, International Association for the Study of Pain (1996).	
	AS	<u>4</u>	Pasternak, G.W., and Letchworth, S.R., "Future opioid analgesics: Targeting the old and the new," Current Opinion in CPNS Investigational Drugs 1:54-64, Current Drugs Ltd (1999).	
	AT	<u>4</u>	Sunshine, A., "Chapter 38. Profile of NSAID + Opioid Combination Analgesics," in Pain: Current Understanding, Emerging Therapies, and Novel Approaches to Drug Discovery, Bountra, C., et al., eds., Marcel Dekker, Inc., New York, NY (May 2003).	
EXAMINER 				
DATE CONSIDERED 11/13/07				
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.				

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 2039.0010001	APPLICATION NO. 10/824,357
	APPLICANT Najib BABUL	
	FILING DATE April 15, 2004	GROUP 1617

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)			
	AR	<u>5</u>	Twycross, R.G., "Chapter 51. Opioids," in <i>Textbook of Pain</i> , 4 th edition, Wall, P.D., and Melzack, R., eds., pp. 1187-1214, Harcourt Publishers Limited, London, England (1999).
	AS	<u>5</u>	Wallace, J., and Chin, B., "Celecoxib GD Searle & Co," <i>Current Opinion in CPNS Investigational Drugs</i> 1:132-141, Current Drugs Ltd (1999).
	AT	<u>5</u>	Hughes, C.E., et al., "Discriminative-Stimulus Effects of Morphine in Combination With α - and δ -Noradrenergic Agonists and Antagonists in Rats," <i>Pharmacol. Biochem. Behav.</i> 53:979-986, Elsevier Science Inc. (1996).
EXAMINER 			DATE CONSIDERED 11/13/07
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.			

FORM PTO-1449 <u>INFORMATION DISCLOSURE STATEMENT</u>	ATTY. DOCKET NO. 2039.0010001	APPLICATION NO. 10/824,357
	APPLICANT Najib BABUL	
	FILING DATE April 15, 2004	GROUP 1617

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)			
	AR	<u>6</u>	Szczeklik, A., et al., "Salmeterol Prevents Aspirin-induced Attacks of Asthma and Interferes with Eicosanoid Metabolism," <i>Am. J. Respir. Crit. Care Med.</i> 158:1168-1172, American Lung Association (1998).
	AS	<u>6</u>	Bentley, G.A., and Starr, J., "The antinociceptive action of some β -adrenoreceptor agonists in mice," <i>Br. J. Pharmacol.</i> 88:515-521, The Macmillan Press Ltd. (1986).
	AT	<u>6</u>	Brochet, D., et al., "Antinociceptive activity of beta-adrenoceptor agonists in the hot plate test in mice," <i>Psychopharmacology</i> 88:527-528, Springer-Verlag (1986).
EXAMINER			DATE CONSIDERED 11/13/07
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.			

FORM PTO-1449 <u>INFORMATION DISCLOSURE STATEMENT</u>	ATTY. DOCKET NO. 2039.0010001	APPLICATION NO. 10/824,357
	APPLICANT Najib BABUL	
	FILING DATE April 15, 2004	GROUP 1617

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						



FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)			
	AR	7	Grubb, M.N., and Burks, T.F., "Selective Antagonism of the Intestinal Stimulatory Effects of Morphine by Isoproterenol, Prostaglandin E ₁ and Theophylline," <i>J. Pharmacol. Exp. Ther.</i> 193:884-891, The Williams & Wilkins Co. (1975).
	AS	7	Kindman, L.A., et al., "Opioids Potentiate Contractile Response of Rabbit Myocardium to the Beta Adrenergic Agonist Isoproterenol," <i>J. Cardiovasc. Pharmacol.</i> 17:61-67, Raven Press, Ltd. (1991).
	AT	7	Koster, A.S., et al., "Glucuronidation of Morphine and Six β_2 -Sympathomimetics in Isolated Rat Intestinal Epithelial Cells," <i>Drug Metab. Dispos.</i> 13:232-238, The American Society for Pharmacology and Experimental Therapeutics (1985).
EXAMINER			DATE CONSIDERED 11/13/07
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.			

FORM PTO-1449 <u>INFORMATION DISCLOSURE STATEMENT</u>	ATTY. DOCKET NO. 2039.0010001	APPLICATION NO. 10/824,357
	APPLICANT Najib BABUL	
	FILING DATE April 15, 2004	GROUP 1617

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						


FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)			
	AR	<u>8</u>	Osada, E., et al., "Pharmacological Studies of Mabuterol, a New Selective β_2 -Stimulant. III: Effects on the central nervous system, striated muscle and carbohydrate and lipid metabolism," <i>Arzneimittelforschung</i> 34:1652-1658, Editio Cantor (1984).
	AS	<u>8</u>	Rees, M.R., et al., "The Effect of β -Adrenoreceptor Agonists and Antagonists on Gastric Emptying in Man," <i>Br. J. Clin. Pharmacol.</i> 10:551-554, Macmillan Publishers Ltd. (1980).
	AT	<u>8</u>	Silvasti, M., et al., "Pharmacokinetic comparison of a dextromethorphan-salbutamol combination tablet and a plain dextromethorphan tablet," <i>Int. J. Clin. Pharmacol. Ther. Toxicol.</i> 28:268-272, Dustri-Verlag Feistle (1990).
EXAMINER 			DATE CONSIDERED 11/13/07
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.			

FORM PTO-1449 <u>INFORMATION DISCLOSURE STATEMENT</u>	ATTY. DOCKET NO. 2039.0010001	APPLICATION NO. 10/824,357
	APPLICANT Najib BABUL	
	FILING DATE April 15, 2004	GROUP 1617

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)			
	AR	9	Yabuuchi, K., et al., "Intracerebroventricular injection of isoproterenol produces its analgesic effect through interleukin-1 β production," <i>Eur. J. Pharmacol.</i> 334:133-140, Elsevier Science B.V. (1997).
	AS		
	AT		

EXAMINER	DATE CONSIDERED 11/13/07
----------	--------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.